方均燕 丁峰 李雪竹

    摘 要 糖尿病是慢性肾脏病和终末期肾脏病的最常见病因，而慢性肾脏病是糖尿病的重要合并症之一，血糖控制不佳会使慢性肾脏病加速进展至终末期肾脏病。因此，控制糖尿病患者的血糖水平至关重要，寻找新方法防治糖尿病肾脏疾病已成为目前重要的医学研究课题之一。胰高血糖素样肽-1相关药物是近年来开发上市的新型降血糖药物，大量临床研究证实其还能降低糖尿病患者的心血管事件发生率，改善合并慢性肾脏病患者的肾脏结局，为糖尿病患者肾脏保护治疗提供了新的选择。本文概要介绍胰高血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂用于糖尿病合并慢性肾脏病患者治疗的研究进展及其临床益处。

    关键词 2型糖尿病 慢性肾脏病 胰高血糖素样肽-1 受体激动剂 二肽基肽酶-4抑制剂

    中图分类号：R977.15； R587.2 文献标志码：A 文章编号：1006-1533(2022)03-0003-05

    Clinical application value of glucagon-like peptide-1-related drugs in patients with diabetes and chronic kidney disease

    FANG Junyan， DING Feng， LI Xuezhu

    (Division of Nephrology， Shanghai Ninth People’s Hospital， Shanghai Jiao Tong University School of Medicine， Shanghai 200011， China)

    ABSTRACT Type 2 diabetes mellitus (T2DM) is the leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD)， whereas CKD is also one of the most important complications of diabetes. Poor glycemic control accelerates the progression of CKD to ESRD. Hence， glycemic control is most important for diabetic patients， and seeking new strategies to prevent diabetic kidney disease have become one of hotspots in medical research. Glucagon-like peptide-1-related drugs have been demonstrated to reduce the risk of adverse cardiovascular events and improve kidney outcomes for patients with T2DM and CKD in a large number of clinical studies and can provide new options for renoprotective therapy for diabetic patients. This article reviews some research progress and clinical benefits of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with diabetes and CKD. ......